Innovation Is 'Our North Star’ Says Illumina Chief
Next-Generation Sequencing Group Eyeing Growing Role For Genomics In Infectious Disease
Executive Summary
The total addressable market for genomics infectious disease testing is increasing, says Illumina, after becoming the first company to receive a US EUA for a next generation sequencing-based COVID-19 test. It came amid a raft of innovation activity and tuck-in M&A for the San Diego group.
You may also be interested in...
First Test That Can Detect COVID-19 Virus Mutations Authorized By FDA
The US FDA on 10 June authorized use of Illumina’s COVIDSeq next generation sequencing diagnostic test to detect the SARS-CoV-2 virus and figure out if it’s mutating. The agency has high hopes this first-of-its-kind test will give researchers a better picture in the ongoing global fight against the COVID-19 pandemic.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.